{"id":"https://genegraph.clinicalgenome.org/r/34cdab4e-7956-4ee7-8ea4-667442326ae9v2.0","type":"EvidenceStrengthAssertion","dc:description":"Variants in *MATR3* were first reported as a cause of autosomal dominant distal myopathy with vocal cord weakness in 2009 (Senderek J, et al., 2009, PMID: 19344878). The *MATR3* gene encodes matrin-3, a highly conserved nuclear matrix protein that binds and interacts with nucleic acids (Belgrader et al., 1991; Hibino et al., 2006). It plays a role in RNA transcription and processing, as well as mRNA stabilization (Hibino et al., 2006). Structurally, the protein includes two zinc finger domains that interact with DNA, along with two domains that bind RNA (Belgrader et al., 1991; Hibino et al., 2006; Salton et al., 2011; Johnson et al., 2014). Heterozygous variants in the *MATR3* gene are asserted to casue amyotrophic lateral sclerosis (ALS) type 21 and distal myopathy with vocal cord and pharyngeal weakness (VCPDM) inherited in an autosomal dominant manner (Senderek et al., 2009; Johnson et al., 2014); the ALS GCEP has lumped these into a single curation for distal myopathy based on an overlap of phenotypes and molecular mechanism. Evidence supporting this gene-disease relationship includes case-level data, segregation data and experimental data. At least 12 missense variants have been reported in 20 probands from 17 publications (PMIDs: 24686783, 28029397, 26493020, 25771394, 26199109, 26708275, 31432357, 31475037, 19344878, 25154462, 25185957, 25952333, 32361838, 29628183, 34659085, 35812165, 39192891). The Ser85Cys variant is recurrent and predominantly found in patients with distal myopathy, however one family was retrospectively diagnose with ALS (PMID: 24686783). Segregation of this variant across 39 patients from 5 families was included in this curation. Experimentally, this gene-disease relationship is supported by the role of *MATR3* as an RNA-binding protein involved in mRNA transport and nuclear export, processes known to be impacted in ALS (PMID: 29109432). Additionally, *MATR3* has been found to bind and interact with critical ALS proteins TDP-43 (PMID: 24686783, 29109432), FUS (PMID: 29109432) and C9orf92 (PMID: 33129345). Further support is provided by a mouse models including overexpression and CRISPR-cas9 knock-in models (PMID: 33082323) that partially recapitulates phenotypic and pathological features. In summary, there is definitive evidence to support the relationship between *MATR3* and autosomal dominant distal myopathy. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time.","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/34cdab4e-7956-4ee7-8ea4-667442326ae9","GCISnapshot":"https://genegraph.clinicalgenome.org/r/97ed1e35-c1b2-40c7-a60e-54b3c24004c4","calculatedEvidenceStrength":"Definitive","changes":[{"id":"cg:newEvidence"},{"id":"cg:classificationChange"},{"id":"cg:otherTextChange"},{"id":"cg:sopChange"},{"id":"cg:summaryChange"}],"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/97ed1e35-c1b2-40c7-a60e-54b3c24004c4_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10096","date":"2024-11-15T15:16:06.372Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/97ed1e35-c1b2-40c7-a60e-54b3c24004c4_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10096","date":"2024-10-08T16:00:00.000Z","role":"Approver"}],"curationReasons":["RecurationNewEvidence","DiseaseNameUpdate"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/97ed1e35-c1b2-40c7-a60e-54b3c24004c4_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e06fe33c-72d4-44ee-8c28-9314ad49f397","type":"EvidenceLine","dc:description":"Analysis of haplotypes for closely flanking and intragenic SNP and STR markers showed no evidence of haplotype sharing between the North American and the Bulgarian VCPDM families, suggests that the same MATR3 mutation arose independently in each of them.\n\nNote, the North American family was scored in PMID: 24686783","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e06fe33c-72d4-44ee-8c28-9314ad49f397_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19344878","allele":{"id":"https://genegraph.clinicalgenome.org/r/86d617af-65b9-43a6-8786-d9dab420a860","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018834.6(MATR3):c.254C>G (p.Ser85Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA123688"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/e06fe33c-72d4-44ee-8c28-9314ad49f397_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"A shift of the subnuclear distribution was seen for the Myc-tagged S85C matrin 3 mutant compared to Myc-tagged wild-type matrin 3 upon overexpression in Cos7 cells. Fractionation of nuclear proteins showed that mutant matrin 3 is almost exclusively confined to the insoluble fraction, whereas with WT a considerable proportion of matrin 3 occurs in the nucleic-acid binding protein fraction.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/6ca0b710-5888-43b8-b233-a0c23bfc3799","type":"EvidenceLine","dc:description":"There is poor coverage of this region but the variant  is present in the gnomAD non-neuro subset v2.1.1 with a MAF of 0.00005929. This variant affects only one of the isoforms and LOF is not a clear mechanism for MATR3, as such this variant is scored 0pt.\n","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6ca0b710-5888-43b8-b233-a0c23bfc3799_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26493020","allele":{"id":"https://genegraph.clinicalgenome.org/r/335d41ff-5a06-43f2-8502-a143ad5625f1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000005.10:g.139294029G>T (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA3432837"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/6ca0b710-5888-43b8-b233-a0c23bfc3799_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"There is supportive RT-PCR data showing this splicing variant inserts 22 amino acids into the MATR3 sequence, there is no other variant level functional data. ","functionalDataSupport":"No"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/e7a77a71-7427-4b4a-9905-99615a0dddb0","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e7a77a71-7427-4b4a-9905-99615a0dddb0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31475037","allele":{"id":"https://genegraph.clinicalgenome.org/r/7950977c-6a65-4724-bf9b-c2b4f58c2ddc","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000005.10:g.139294011C>T (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA128742346"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/e7a77a71-7427-4b4a-9905-99615a0dddb0_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"P11S is present in isoform b of MATR3 only, and may contribute to splicing alterations of other isoforms (discussed in publication without functional support).","functionalDataSupport":"No"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/71661e91-d412-42b5-8334-3a7b9545a563","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/71661e91-d412-42b5-8334-3a7b9545a563_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26708275","allele":{"id":"https://genegraph.clinicalgenome.org/r/37ad8fca-3209-4967-bd6a-725d3162f275","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018834.6(MATR3):c.1829C>T (p.Ser610Phe)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA361143645"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/6406ec0b-1b49-4b69-b138-b05f5140910e","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6406ec0b-1b49-4b69-b138-b05f5140910e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24686783","allele":{"id":"https://genegraph.clinicalgenome.org/r/7acc10fe-65c8-40e5-aab2-b178a329821e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018834.6(MATR3):c.460C>T (p.Pro154Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA151206"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/6406ec0b-1b49-4b69-b138-b05f5140910e_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In PMID: 29109432 theP154S variant led to MATR3 re-distribution within the nucleus, decreased co-localization with endogenous Matrin 3 and increased co-localization with specific TREX (mRNA nuclear export) components in stably transfected NSC-34 cells.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/e12776ef-2929-4a63-afe7-9f6d6c2a805e","type":"EvidenceLine","dc:description":"Additional Italian patient","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e12776ef-2929-4a63-afe7-9f6d6c2a805e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35812165","allele":{"id":"https://genegraph.clinicalgenome.org/r/86d617af-65b9-43a6-8786-d9dab420a860"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/e12776ef-2929-4a63-afe7-9f6d6c2a805e_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"see previous publications","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/56b3b822-07c0-4f7f-b6eb-584fa2d22bc6","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/56b3b822-07c0-4f7f-b6eb-584fa2d22bc6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24686783","allele":{"id":"https://genegraph.clinicalgenome.org/r/86d617af-65b9-43a6-8786-d9dab420a860"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/56b3b822-07c0-4f7f-b6eb-584fa2d22bc6_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Co-immunoprecipitation experiments used to analyse the known interaction of MATR3 and ALS protein TDP-43 identified that p.Ser85Cys had increased affinity for binding TDP-43, compared to WT. Additionally, expression of MATR3 S85C was reduced compared to WT and other mutations, suggesting a structural effect of the mutations. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/9ffdef43-47fd-457c-8b02-99fdf82d0596","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9ffdef43-47fd-457c-8b02-99fdf82d0596_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28029397","allele":{"id":"https://genegraph.clinicalgenome.org/r/0e32f272-93da-41ac-bfd7-6e166cb6027d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018834.6(MATR3):c.457G>T (p.Gly153Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA361487311"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/7740ab36-d99c-46eb-8c9a-9416100cf8a2","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7740ab36-d99c-46eb-8c9a-9416100cf8a2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25771394","allele":{"id":"https://genegraph.clinicalgenome.org/r/27e9636a-f14d-45be-b8e6-24aef165cc13","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018834.6(MATR3):c.214G>A (p.Ala72Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA361486768"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/1b82dd2a-2d6f-48b4-a999-4bbac93fa237","type":"EvidenceLine","dc:description":"This variant (p.A378T) is present in a single SALS case with no supportive functional data.  It is present in the non-neuronal gnomAD subset v2.1.1 at a MAF of 0.0001352 (in 24 alleles) which was considered too frequent to a plausible cause.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1b82dd2a-2d6f-48b4-a999-4bbac93fa237_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32028661","allele":{"id":"https://genegraph.clinicalgenome.org/r/f41b3ee0-0877-4e36-a19d-87f0d434f9cd","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018834.6(MATR3):c.1132G>A (p.Ala378Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/651450"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/f4cbd04d-2d18-4f0e-9774-fcb8f217f048","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f4cbd04d-2d18-4f0e-9774-fcb8f217f048_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28029397","allele":{"id":"https://genegraph.clinicalgenome.org/r/ce62df9d-d420-4b10-8b76-2776e2506d16","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018834.6(MATR3):c.196C>A (p.Gln66Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA361486725"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/41ecb1f5-3bc9-45e5-af97-580bba2b0415","type":"EvidenceLine","dc:description":"Second American family identified with Ser85Cys","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/41ecb1f5-3bc9-45e5-af97-580bba2b0415_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25952333","allele":{"id":"https://genegraph.clinicalgenome.org/r/86d617af-65b9-43a6-8786-d9dab420a860"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/41ecb1f5-3bc9-45e5-af97-580bba2b0415_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"See previous publications","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/f3a02d2e-4f2b-4499-9e64-468c27bb713b","type":"EvidenceLine","dc:description":"This is an additional German family to those already reported. The authors also identified three further unrelated German patients.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f3a02d2e-4f2b-4499-9e64-468c27bb713b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32361838","allele":{"id":"https://genegraph.clinicalgenome.org/r/86d617af-65b9-43a6-8786-d9dab420a860"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/f3a02d2e-4f2b-4499-9e64-468c27bb713b_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"see previous publications","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/37e4e046-4725-4b15-81a2-2b9226cafc40","type":"EvidenceLine","dc:description":"First Russian family reported with this variant. Three additionally Russian families, with 7 genotyped patients, were also reported.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/37e4e046-4725-4b15-81a2-2b9226cafc40_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/39192891","allele":{"id":"https://genegraph.clinicalgenome.org/r/86d617af-65b9-43a6-8786-d9dab420a860"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/37e4e046-4725-4b15-81a2-2b9226cafc40_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"See previous publications","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/712bb46e-794d-48c1-89c2-e277093aef35","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/712bb46e-794d-48c1-89c2-e277093aef35_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31432357","allele":{"id":"https://genegraph.clinicalgenome.org/r/da840954-f275-4080-b3fa-13c976eb6f6b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018834.6(MATR3):c.2213A>G (p.Glu738Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/569504"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/bb330827-3591-4e38-a2db-2062f3504fab","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bb330827-3591-4e38-a2db-2062f3504fab_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24686783","allele":{"id":"https://genegraph.clinicalgenome.org/r/c6972505-169a-45db-87b7-79b673f3aaf7","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018834.6(MATR3):c.1864A>G (p.Thr622Ala)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA151204"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/bb330827-3591-4e38-a2db-2062f3504fab_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In PMID: 30015619 primary rat neuronal cultures were transfected with MATR3-EGFP WT or mutant forms. WT is toxic but T622A  significantly increased risk of death over WT.\n","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/176a7ffb-f8af-4c4c-ac39-7ac7f95c8cfd","type":"EvidenceLine","dc:description":"The family was re-studied and found to have a pathogenic KIF5A mutation that segregates with newly identified affected individuals and produces the same exon 27 exclusion seen in KIF5A families.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/176a7ffb-f8af-4c4c-ac39-7ac7f95c8cfd_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24686783","allele":{"id":"https://genegraph.clinicalgenome.org/r/d2036413-5438-46c0-9378-0103ac2a4bf8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018834.6(MATR3):c.344T>G (p.Phe115Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA151202"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/176a7ffb-f8af-4c4c-ac39-7ac7f95c8cfd_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Co-immunoprecipitation experiments used to analyse the known interaction of MATR3 and ALS protein TDP-43 identified p.F115C mutant MATR3 did bind with TDP-43. A knock-in a mouse model did not have strong recapitulation of ALS features (PMID: 30563574).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/b7baed62-6389-4ae6-bd3a-0730e57447f4","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b7baed62-6389-4ae6-bd3a-0730e57447f4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26493020","allele":{"id":"https://genegraph.clinicalgenome.org/r/94b82f99-77e7-4a4f-ab8a-72ccc5b4ba91","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018834.6(MATR3):c.1180G>A (p.Val394Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA361139645"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/4c49379d-c125-4df0-bc9f-f3db4851d658","type":"EvidenceLine","dc:description":"First French patient reported. No haplotype analysis.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4c49379d-c125-4df0-bc9f-f3db4851d658_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29628183","allele":{"id":"https://genegraph.clinicalgenome.org/r/86d617af-65b9-43a6-8786-d9dab420a860"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/4c49379d-c125-4df0-bc9f-f3db4851d658_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"see previous publications","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/a842fe8a-02e8-422f-ab0a-44e916d53d5e","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a842fe8a-02e8-422f-ab0a-44e916d53d5e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31475037","allele":{"id":"https://genegraph.clinicalgenome.org/r/addd42d5-b799-40a0-8a28-0868c067ce3e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018834.6(MATR3):c.824G>A (p.Ser275Asn)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA361488151"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/97ed1e35-c1b2-40c7-a60e-54b3c24004c4_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/684b5867-cbaa-4fbe-9b33-ff181a25392c_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/39192891","rdfs:label":"Family 2","estimatedLodScore":2.11,"family":{"id":"https://genegraph.clinicalgenome.org/r/684b5867-cbaa-4fbe-9b33-ff181a25392c","type":"Family","rdfs:label":"Family 2","member":{"id":"https://genegraph.clinicalgenome.org/r/d09a472d-b9ab-4c5c-8ee5-e66631db5617","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/39192891","rdfs:label":"2.1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":48,"allele":{"id":"https://genegraph.clinicalgenome.org/r/86d617af-65b9-43a6-8786-d9dab420a860"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"CK 604 U/L","phenotypes":["obo:HP_0001618","obo:HP_0200101","obo:HP_0030319","obo:HP_0002938","obo:HP_0002515","obo:HP_0002015","obo:HP_0003484","obo:HP_0007340","obo:HP_0009027","obo:HP_0033202","obo:HP_0002378","obo:HP_0003376"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/37e4e046-4725-4b15-81a2-2b9226cafc40_variant_evidence_item"}}},"meetsInclusionCriteria":true,"phenotypePositiveAllelePositive":5,"proband":{"id":"https://genegraph.clinicalgenome.org/r/d09a472d-b9ab-4c5c-8ee5-e66631db5617"},"sequencingMethod":{"id":"cg:AllGenesSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/2bdee129-98d4-49d1-90ee-393381039dba_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19344878","rdfs:label":"Bulgarian Family","estimatedLodScore":4.21,"family":{"id":"https://genegraph.clinicalgenome.org/r/2bdee129-98d4-49d1-90ee-393381039dba","type":"Family","rdfs:label":"Bulgarian Family","member":{"id":"https://genegraph.clinicalgenome.org/r/f959bd07-695d-4872-b996-c6340e1cbf1a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19344878","rdfs:label":"54M","ageType":"AgeAtReport","ageUnit":"Years","ageValue":54,"allele":{"id":"https://genegraph.clinicalgenome.org/r/86d617af-65b9-43a6-8786-d9dab420a860"},"firstTestingMethod":"Linkage analysis","phenotypeFreeText":"\"typical VCPDM (vocal cord and pharyngeal weakness with distal myopathy) phenotype\"","phenotypes":["obo:HP_0003198","obo:HP_0008959","obo:HP_0002460","obo:HP_0009053","obo:HP_0003736","obo:HP_0003236"],"previousTestingDescription":"no MYOT mutation was detected","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/e06fe33c-72d4-44ee-8c28-9314ad49f397_variant_evidence_item"}}},"meetsInclusionCriteria":true,"phenotypePositiveAllelePositive":10,"phenotypes":["obo:HP_0002460","obo:HP_0003236"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/f959bd07-695d-4872-b996-c6340e1cbf1a"},"publishedLodScore":3.35,"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/f33b59ab-950a-4bd5-a8a6-a731ae25f777_proband_segregation","type":"FamilyCosegregation","dc:description":"Linkage analysis was preformed in the original family publications (PMID: 19344878, 9837826).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24686783","rdfs:label":"USALS#4","estimatedLodScore":3.01,"family":{"id":"https://genegraph.clinicalgenome.org/r/f33b59ab-950a-4bd5-a8a6-a731ae25f777","type":"Family","rdfs:label":"USALS#4","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/2033f756-7b50-4442-9fe9-06aa5bef1183","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24686783","rdfs:label":"Individual IV-10","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":44,"allele":{"id":"https://genegraph.clinicalgenome.org/r/86d617af-65b9-43a6-8786-d9dab420a860"},"detectionMethod":"Refined linkage loci, prioritised genes for distal myopathies and related disorders and preformed Sanger sequencing on 20 genes","firstTestingMethod":"Linkage analysis","phenotypeFreeText":"onset with right foot drop, muscle weakness speeding to other limbs. Initial diagnosis of CMT, then distal myopathy before reclassification of ALS","phenotypes":["obo:HP_0002093","obo:HP_0001260","obo:HP_0001324"],"previousTesting":false,"secondTestingMethod":"PCR","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/56b3b822-07c0-4f7f-b6eb-584fa2d22bc6_variant_evidence_item"}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"Family originally diagnosed with distal asymmetrical myopathy with vocal cord paralysis (MONDO:0018951) and retrospectively diagnosed with ALS after development of progressive respiratory failure resulting in death, typically after fifteen years of illness.\nOnset with foot drop common, dysarthria also common.\n\"In summary, the clinical features of patients in the Ser85Cys MATR3 kindred were consistent with a progressive, fatal motor neuron disease with combined upper and lower motor neuron signs, bulbar dysfunction and respiratory failure\"\nSee https://www.nature.com/articles/nn.3688#Sec2.","phenotypePositiveAllelePositive":11,"phenotypes":["obo:HP_0001260","obo:HP_0002093","obo:HP_0001605"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/2033f756-7b50-4442-9fe9-06aa5bef1183"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/978155f8-d352-48cb-b374-354a1ac55cc3_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28029397","rdfs:label":"Family p.G153C","family":{"id":"https://genegraph.clinicalgenome.org/r/978155f8-d352-48cb-b374-354a1ac55cc3","type":"Family","rdfs:label":"Family p.G153C","member":{"id":"https://genegraph.clinicalgenome.org/r/50e0f8cb-ac56-4a17-89cb-6f0a0e4d4079","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28029397","rdfs:label":"Patient 4","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":52,"allele":{"id":"https://genegraph.clinicalgenome.org/r/0e32f272-93da-41ac-bfd7-6e166cb6027d"},"detectionMethod":"HaloPlex Custom kit (Agilent Technologies, Santa Clara, CA, USA)\nThe HaloPlex panel was designed to target the following genes: ANG, ATXN2, C9orf72, CHCHD10, CHMP2B, CHRNA4, DAO, DCTN1, EPHA4, EWSR1, FIG4, FUS, GLE1, GRN, HNRNPA1, HNRNPA2B1, MAPT, MATR3, NIPA1, OPTN, PFN1, SETX, SIGMAR1, SOD1, SQSTM1, SS18L1, TAF15, TARDBP, TBK1, TUBA4A, UBQLN2, VAPB, and VCP.\nCoding variants were confirmed by Sanger sequencing. Expansions in C9orf72 and ATXN2 were excluded in all patients by standard protocols.","firstTestingMethod":"Next generation sequencing panels","phenotypeFreeText":"upper motor neuron dominant\nProband - male, onset at 52y in upper limb","phenotypes":"obo:HP_0001324","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/9ffdef43-47fd-457c-8b02-99fdf82d0596_variant_evidence_item"}}},"phenotypeFreeText":"onset in lower limb, upper motor neuron dominant\nProband - =male, onset at 56y","phenotypePositiveAllelePositive":1,"phenotypes":["obo:HP_0002093","obo:HP_0002015","obo:HP_0001324","obo:HP_0001260"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/50e0f8cb-ac56-4a17-89cb-6f0a0e4d4079"}},{"id":"https://genegraph.clinicalgenome.org/r/596cd84e-2b0f-433c-a3b4-3fb96715347d_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32361838","rdfs:label":"Family I","estimatedLodScore":2.11,"family":{"id":"https://genegraph.clinicalgenome.org/r/596cd84e-2b0f-433c-a3b4-3fb96715347d","type":"Family","rdfs:label":"Family I","member":{"id":"https://genegraph.clinicalgenome.org/r/f566ab40-e1c5-4d9a-bb90-032121e52335","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32361838","rdfs:label":"Patient no. 1","allele":{"id":"https://genegraph.clinicalgenome.org/r/86d617af-65b9-43a6-8786-d9dab420a860"},"detectionMethod":"\"genetically confirmed\"","phenotypeFreeText":"Whole-body MRI showed a predominant affection of the distal lower extremities. Lower legs showed a severe fatty infiltration, prominently affecting gastrocnemius and soleus muscle. In thighs, a preferential involvement of semimembranous and biceps femoris muscle was observed. Severe affection of gluteus minimus muscle as well as axial musculature, mainly affecting the thoracic segments, was seen. ","phenotypes":"obo:HP_0003198","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/f3a02d2e-4f2b-4499-9e64-468c27bb713b_variant_evidence_item"}}},"meetsInclusionCriteria":true,"phenotypePositiveAllelePositive":8,"phenotypes":"obo:HP_0003198","proband":{"id":"https://genegraph.clinicalgenome.org/r/f566ab40-e1c5-4d9a-bb90-032121e52335"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/2e5e104d-8704-4b21-8462-384bbbb806f9_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25154462","rdfs:label":"Family C","estimatedLodScore":1.81,"family":{"id":"https://genegraph.clinicalgenome.org/r/2e5e104d-8704-4b21-8462-384bbbb806f9","type":"Family","rdfs:label":"Family C","member":{"id":"https://genegraph.clinicalgenome.org/r/b268f820-2b8a-4807-a838-29698467eee0","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25154462","rdfs:label":"CIII6","ageType":"AgeAtReport","ageUnit":"Years","ageValue":51,"allele":{"id":"https://genegraph.clinicalgenome.org/r/86d617af-65b9-43a6-8786-d9dab420a860"},"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"onset at 47 years ","phenotypes":["obo:HP_0008959","obo:HP_0009053","obo:HP_0008994","obo:HP_6000490","obo:HP_0008997","obo:HP_0001611"],"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/8fa2045f-f0f1-407f-83dc-e83b18434fcc_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25154462","allele":{"id":"https://genegraph.clinicalgenome.org/r/86d617af-65b9-43a6-8786-d9dab420a860"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"meetsInclusionCriteria":true,"phenotypePositiveAllelePositive":5,"phenotypes":["obo:HP_0008959","obo:HP_0008994","obo:HP_0008997","obo:HP_0009053"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/b268f820-2b8a-4807-a838-29698467eee0"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/63600efe-2d17-4f11-b6fa-7dac02e56250_proband_segregation","type":"FamilyCosegregation","dc:description":"The family was re-studied and found to have a pathogenic KIF5A mutation that segregates with newly identified affected individuals and produces the same exon 27 exclusion seen in KIF5A families.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24686783","rdfs:label":"USALS#3","estimatedLodScore":1.2,"family":{"id":"https://genegraph.clinicalgenome.org/r/63600efe-2d17-4f11-b6fa-7dac02e56250","type":"Family","rdfs:label":"USALS#3","member":{"id":"https://genegraph.clinicalgenome.org/r/b9333d30-22c0-4a39-aa5e-e9b9ed76a5e4","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24686783","rdfs:label":"Individual III-11","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":50,"allele":{"id":"https://genegraph.clinicalgenome.org/r/d2036413-5438-46c0-9378-0103ac2a4bf8"},"detectionMethod":"Analysis of WES data found two novel variants (other in LMNB1 gene) in affected individuals. Variants were absent in controls: Exome Sequencing Project (n=13000 chromosomes), 1000Genomes (2184 chromosomes), dbSNP(build unknown), Human diversity panel (2102 chromosomes), and 5190 controls (in house screening, MATR3 variant only).","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"onset with dysarthria, followed by leg and foot stiffness\ndistal weakness in upper and lower extremities, mild cognitive impairment","phenotypes":["obo:HP_0001324","obo:HP_0100543","obo:HP_0001260"],"previousTesting":false,"previousTestingDescription":"negative for C9orf72 expansion","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/176a7ffb-f8af-4c4c-ac39-7ac7f95c8cfd_variant_evidence_item"}}},"meetsInclusionCriteria":false,"phenotypeFreeText":"One MATR3 carrier diagnosed with dementia. Mild cognitive impairment in proband\nPresentation with either hand weakness or dysarthria common, though limb onset was most common.","phenotypePositiveAllelePositive":6,"phenotypes":["obo:HP_0000726","obo:HP_0001260"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/b9333d30-22c0-4a39-aa5e-e9b9ed76a5e4"}},{"id":"https://genegraph.clinicalgenome.org/r/b8bb4ad2-d385-40f7-b0d5-5dcce75c97e4_proband_segregation","type":"FamilyCosegregation","dc:description":"Not enough segregations (4 or more needed for autosomal dominant families) to score linkage here.\nLinkage analysis not completed on the family","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24686783","rdfs:label":"ITALS#10","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/b8bb4ad2-d385-40f7-b0d5-5dcce75c97e4","type":"Family","rdfs:label":"ITALS#10","member":{"id":"https://genegraph.clinicalgenome.org/r/19a8ff6b-acd9-4ef3-94fa-b8737505aa46","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24686783","rdfs:label":"Individual III-1","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":62,"allele":{"id":"https://genegraph.clinicalgenome.org/r/c6972505-169a-45db-87b7-79b673f3aaf7"},"detectionMethod":"Part of a panel of 108 FALS cases that underwent WES","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Onset with left foot drop, cognitively normal, uses noninvasive ventilation, still alive after 32 months","phenotypes":"obo:HP_0001324","previousTesting":true,"previousTestingDescription":"negative for mutations in known ALS-associated genes, including the pathogenic hexanucleotide repeat expansion of C9ORF72","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/bb330827-3591-4e38-a2db-2062f3504fab_variant_evidence_item"}}},"meetsInclusionCriteria":false,"phenotypeFreeText":"Limb onset in left foot and right arm","phenotypePositiveAllelePositive":3,"phenotypes":["obo:HP_0001324","obo:HP_0002093"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/19a8ff6b-acd9-4ef3-94fa-b8737505aa46"}},{"id":"https://genegraph.clinicalgenome.org/r/e21eb44e-7637-4f80-977c-4f64a834cb71_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25952333","rdfs:label":"American Family","estimatedLodScore":0.9,"family":{"id":"https://genegraph.clinicalgenome.org/r/e21eb44e-7637-4f80-977c-4f64a834cb71","type":"Family","rdfs:label":"American Family","member":{"id":"https://genegraph.clinicalgenome.org/r/9a77ed4a-4d34-4d90-b22f-9a5240cc016f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25952333","rdfs:label":"II.2","allele":{"id":"https://genegraph.clinicalgenome.org/r/86d617af-65b9-43a6-8786-d9dab420a860"},"phenotypeFreeText":"First manifestation was either weakness in the hands or legs causing difficulty in dexterity, or standing on heels and toes. Creatine kinase (CK) levels were normal or marginally elevated.  Numerous rimmed-vacuolated fibres.","phenotypes":["obo:HP_0003198","obo:HP_0003701"],"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/41ecb1f5-3bc9-45e5-af97-580bba2b0415_variant_evidence_item"}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":4,"proband":{"id":"https://genegraph.clinicalgenome.org/r/9a77ed4a-4d34-4d90-b22f-9a5240cc016f"}},{"id":"https://genegraph.clinicalgenome.org/r/c697b320-d10a-4f7f-b773-20ade9037d86_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25185957","rdfs:label":"Asian Family","estimatedLodScore":0.3,"family":{"id":"https://genegraph.clinicalgenome.org/r/c697b320-d10a-4f7f-b773-20ade9037d86","type":"Family","rdfs:label":"Asian Family","member":{"id":"https://genegraph.clinicalgenome.org/r/340ca4a4-e473-4901-b991-d5a3ece428ce","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25185957","rdfs:label":"Case 2","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":63,"allele":{"id":"https://genegraph.clinicalgenome.org/r/86d617af-65b9-43a6-8786-d9dab420a860"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Myogenic and neurogenic EMG, axonal degeneration type motorsensory polyneuropathy. Did not fulfil diagnostic criteria of ALS because they lacked upper motor neuron signs.","phenotypes":["obo:HP_0002094","obo:HP_0002329","obo:HP_0012534","obo:HP_0001611","obo:HP_0002015","obo:HP_0009053","obo:HP_0001284","obo:HP_0008959","obo:HP_0001260"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/0fe0a0da-7640-475d-ab6a-664455a7b155_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25185957","allele":{"id":"https://genegraph.clinicalgenome.org/r/86d617af-65b9-43a6-8786-d9dab420a860"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0002015","obo:HP_0009053"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/340ca4a4-e473-4901-b991-d5a3ece428ce"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":1.8},{"id":"https://genegraph.clinicalgenome.org/r/8fa2045f-f0f1-407f-83dc-e83b18434fcc","type":"EvidenceLine","dc:description":"Haplotype analysis suggests the variant arose independently from North American and Bulgarian families. The same haplotype was shared by five other German families with 9 patients harboring the same variant.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8fa2045f-f0f1-407f-83dc-e83b18434fcc_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/8fa2045f-f0f1-407f-83dc-e83b18434fcc_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"See previous publications","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/1ca133af-1793-4dea-9fae-6f5399605e93","type":"EvidenceLine","dc:description":"First Italian patient reported. No haplotype analysis. ","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1ca133af-1793-4dea-9fae-6f5399605e93_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34659085","allele":{"id":"https://genegraph.clinicalgenome.org/r/86d617af-65b9-43a6-8786-d9dab420a860"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/1ca133af-1793-4dea-9fae-6f5399605e93_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"See previous publications","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/756ad931-807d-40a8-8439-1e321b37babc","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/756ad931-807d-40a8-8439-1e321b37babc_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26199109","allele":{"id":"https://genegraph.clinicalgenome.org/r/b0fc214d-0fca-4418-9cc4-bb0d95be1093","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018834.6(MATR3):c.439A>T (p.Arg147Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA361487268"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/12b086ac-514d-4ce4-b77d-e13ebfdd4aa0","type":"EvidenceLine","dc:description":"The total allele frequency in gnomADv2.1 non-neuro is 0.000009647 above the <0.000005 threshold set by the ALS GCEP.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/12b086ac-514d-4ce4-b77d-e13ebfdd4aa0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28029397","allele":{"id":"https://genegraph.clinicalgenome.org/r/2611654e-0d4e-4ae5-bd5d-738939596535","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018834.6(MATR3):c.2120C>T (p.Ser707Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA361144973"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/6012cb46-9f37-440b-b964-b384917e2de7","type":"EvidenceLine","dc:description":"This splicing variant (c.-3392T>A) was identified in a SALS case. It is predicted to affect the donor splicing site of the noncoding exon 2 of three MATR3 isoforms. There was no supportive RT-PCR data to determine the effect of this splicing variant on protein sequence, nor other functional supportive data. RT-PCR was not preformed because of the varaint's location in the noncoding 5'UTR of MATR3. The variant has an rsID (rs539017488). Though it has a low frequency in the non-neuro GnomAD v2.1.1 subset (MAF=0.00008046), it was scored 0, due to its position in noncoding exon 2 or 5'UTR of MATR3, and the lack of RT-PCR data.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6012cb46-9f37-440b-b964-b384917e2de7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26493020","allele":{"id":"https://genegraph.clinicalgenome.org/r/7e64c7fb-d6c4-4c88-995a-ee6b6837b9fd","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000005.10:g.139276152T>A (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA128740404"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/9a21b142-1e2a-479f-99af-c49287cdc8fc","type":"EvidenceLine","dc:description":"This variant was identified in a SALS case, with no supportive functional data. Predicted to be pathogenic by 2/3 tools (Poly-Phen-2 and MutationTaster). A score of 0 was given due to presence in control databases with a global MAF of 0.002 (rsID rs139589527). The variant is present in ClinVar, classified as benign. The non-neuronal GnomAD v2.1.1 subset frequency is 0.000279.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9a21b142-1e2a-479f-99af-c49287cdc8fc_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28029397","allele":{"id":"https://genegraph.clinicalgenome.org/r/536286bf-ecaf-4968-8daf-ac5623eec395","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018834.6(MATR3):c.1991A>C (p.Glu664Ala)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA3433283"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/0fe0a0da-7640-475d-ab6a-664455a7b155","type":"EvidenceLine","dc:description":"First report of S85C in an Asian family with VCPDM. Haplotype analysis not reported.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0fe0a0da-7640-475d-ab6a-664455a7b155_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/0fe0a0da-7640-475d-ab6a-664455a7b155_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"See previous publications.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/05f3374a-1610-4724-b784-913b8f47df98","type":"EvidenceLine","dc:description":"This variant was identified in a SALS case, with no supportive functional data. Predicted to be pathogenic by 1/3 tools (MutationTaster). A score of 0 was given due to presence in control databases (incl 13 of 6490 samples in the NHLBI Exome Sequencing Project) with a global MAF of 0.0018 (rsID rs148402819). The variant is present in ClinVar, classified as benign. The non-neuronal GnomAD v2.1.1 subset frequency is 0.0003881. This variant was identified in a SALS case and classified as benign in another publication (PMID:25771394).","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/05f3374a-1610-4724-b784-913b8f47df98_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28029397","allele":{"id":"https://genegraph.clinicalgenome.org/r/fd700e47-caf1-4be0-9ba8-265d498ae8dc","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018834.6(MATR3):c.2360A>G (p.Asn787Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA3433426"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":7.65},{"id":"https://genegraph.clinicalgenome.org/r/97ed1e35-c1b2-40c7-a60e-54b3c24004c4_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/97ed1e35-c1b2-40c7-a60e-54b3c24004c4_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d2704ac7-b2ae-41a3-86d1-e21e4d789e77","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d966aed0-d3ef-4b41-8cbc-3c9154679813","type":"Finding","dc:description":"Compared to control spinal cord tissues, MATR3 expression was found to exhibit strong nuclear ad cytoplasmic immunoreactivity. Strong glial staining was also evident in ALS patients. \nMATR3 protein aggregates in nucleus were noted in a small number of cases, including an ALS patient with the pathological C9orf72 repeat expansion.\nNo differences in MATR3 staining were noted between MATR3 Phe115Cys patient compared to other ALS patients.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24686783","rdfs:label":"MATR3 Immunohistochemistry in ALS patient spinal cord","demonstrates":{"id":"cg:GeneExpressionB"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/a6f11ff1-c23d-4bfa-89b8-b6b437c80526","type":"EvidenceLine","dc:description":"Here it was shown that the ALS-associated RNA-binding protein, Matrin-3 (MATR3), colocalizes with G4C2 RNA foci in patient tissues as well as iPSC-derived motor neurons harboring the C9orf72 mutation. Hyperexpansion of C9 repeats perturbed subcellular distribution and levels of endogenous MATR3 in C9-ALS patient-derived motor neurons.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/68c06420-4ba6-4c86-8e14-8391ae9a2f61","type":"Finding","dc:description":"Using fluorescent in situ hybridization (FISH) coupled with immunocytochemistry, the authors analyzed the nuclei of these cells and observed colocalization between G4C2 RNA foci and MATR3 in two independent C9-ALS patient-derived iPSC-MNs. There was apparent colocalization between G4C2 foci with both punctate and diffuse forms of MATR3 within the nuclei of C9 iPSC-MNs.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33129345","rdfs:label":"physical interaction between G4C2 RNA and MATR3","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/16a4cabf-32f0-4bcd-b969-10636619ec43","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4cdcc202-fa40-464c-9ca8-eecd2d29e7ef","type":"Finding","dc:description":"Figure 3 and Figure S4","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24686783","rdfs:label":"TDP-43 interaction","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/4edd1012-d774-43c5-9eff-be8f2e60e42d","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3d177edf-e1ad-48f9-b732-0cb89c3a6b40","type":"Finding","dc:description":"Many ALS genes have known functions in RNA processing, including mRNA transport. Recently,  the C9orf72 pathological repeat expansion has been associated with impaired nuclear transport (see PMID: 27087014 for review).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29109432","rdfs:label":"Immunoprecipitation and mass spectrometry ","demonstrates":{"id":"cg:BiochemicalFunctionA"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/97ed1e35-c1b2-40c7-a60e-54b3c24004c4_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/339f9a7c-72cc-4d52-aba7-c86e81a626fd","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/82d121ed-24af-4f34-baf8-ff877e7d707a","type":"FunctionalAlteration","dc:description":"SH-SY5Y cells were co-transfected with the constructs of aggregation-prone TDP-43 and wild-type or mutant MATR3. WT MATR3 resulted in no change on percent of cells with aggregates, however the S85C mutation caused 30% increase in cells with aggregates.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32731393","rdfs:label":"TDP-43 Aggregation"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/e29c83b7-3796-47c9-b354-968667d07a3e","type":"EvidenceLine","dc:description":"This evidence score was increased to 1 due to the direct link of multiple MATR3 mutations with ALS proteins TDP-43 and FUS.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ff996b33-fdf9-4388-ba7a-e3677c18bfac","type":"FunctionalAlteration","dc:description":"1) There was a statistically significant increase in polyA-mRNA nuclear to cytoplasmic ratio in cells expressing S85C and P154S Matrin 3, suggesting these mutations induce significant defects in mRNA nuclear transport.\n\n2) Matrin 3 mutations led to an increase in the nuclear to cytoplasmic ratio of TDP-43 mRNA compared to an empty vector control. The nuclear to cytoplasmic ratio of FUS mRNA was increased by expression of S85C, P154S and T622A Matrin 3 mutants.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29109432","rdfs:label":"co-immunoprecipitation, co-immunofluorescence "}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/f3fc96ae-c0eb-4174-8652-58ea6c257056","type":"EvidenceLine","dc:description":"In contrast to other RNA-binding proteins associated with ALS, cytoplasmic MATR3 redistribution mitigated neurodegeneration, suggesting that nuclear MATR3 mediates toxicity. These findings offer a foundation for understanding MATR3-related neurodegeneration and how nucleic acid binding functions, localization, and pathogenic mutations drive sporadic and familial disease.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d217502c-af98-4399-9fec-f73886b902d8","type":"FunctionalAlteration","dc:description":"Using a rat primary neuron model to assess MATR3-mediated toxicity, the authors noted that neurons were bidirectionally vulnerable to MATR3 levels, with pathogenic MATR3 mutants displaying enhanced toxicity. Primary rat neuronal cultures were transfected with MATR3-EGFP WT or mutant forms. WT is toxic but the mutants (S85C, F115C, P154S, T622A) significantly increased risk of death over WT (average 3 fold above endogenous).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30015619","rdfs:label":"Enhanced toxicity"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/97ed1e35-c1b2-40c7-a60e-54b3c24004c4_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/04bde958-aaae-4a93-8068-58acdd5159e8","type":"EvidenceLine","dc:description":"This model is downgraded to 0.5pt because the phenotype only occurs in homozygosity and the motor neuron deficit trend is not statistically significant. Additionally, some motor phenotype is likely explained by the profound loss of cerebellar purkinje cells.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f714e85a-5c7d-4ffa-aef3-0e442910848a","type":"Finding","dc:description":"Mice expressing S85C mutant Matr3 in the homozygous state showed progressive muscle deficits - a phenotype of ALS in humans. They also showed weight loss and health decline, resulting in reaching ethical end-stage before WT mice.\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33082323","rdfs:label":"mouse model of MATR3 p.Ser85Cys","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/675bd7f7-dc64-4202-9dd8-2617152bfe8c","type":"EvidenceLine","dc:description":"The Phe115Cys variant in this mouse model is no longer considered causative of ALS. Additionally, the overexpression four times higher than the WT line and only muscle pathology is seen, with exclusion of motor neuron disease, so does not faithfully show ALS.","calculatedScore":2,"direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/55a64e40-7e23-4eb3-8daf-972515833a8f","type":"Finding","dc:description":"Muscle weakness in the limbs is a characteristic feature of ALS.\nThe F115C MATR3 mouse developed profound motor phenotype and showed gross muscle atrophy.\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30563574","rdfs:label":"Expression of human MATR3 in mice","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":4.5}],"evidenceStrength":"Definitive","sequence":9367,"specifiedBy":"GeneValidityCriteria11","strengthScore":12.15,"subject":{"id":"https://genegraph.clinicalgenome.org/r/tFb5lVWTyls","type":"GeneValidityProposition","disease":"obo:MONDO_0018951","gene":"hgnc:6912","modeOfInheritance":"obo:HP_0000006"},"version":"2.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_97ed1e35-c1b2-40c7-a60e-54b3c24004c4-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}